Quick Takeaways
- Mittie Doyle has 3 issuer positions tracked on this page.
- Estimated disclosed ownership value: $65,240.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Mittie Doyle
- Location
- South San Francisco, CA
- Summary
- The estimated net worth of Mittie Doyle is at least $65,240 dollars as of 08 Apr 2026. Mittie Doyle is the Chief Medical Officer of Avalo Therapeutics, Inc. and owns shares of Avalo Therapeutics, Inc. (AVTX) stock worth about $65.2K.
- Signature
- /s/ Christopher Sullivan, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Mittie Doyle and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Avalo Therapeutics, Inc. ($65,240).
- Past-year value change for that position: -$493,979.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Mittie Doyle
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | Chief Medical Officer | $65,240 | -$493,979 | -88% | 06 Apr 2026 |
| CGEM | Cullinan Therapeutics, Inc. | Director | 07 Aug 2025 | |||
| DICE | DICE Therapeutics, Inc. | Director | 09 Aug 2023 |
Insider Transactions Reported by Mittie Doyle:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.